Catabasis Pharma (CATB) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Catabasis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Corporate Highlights
November 12, 2015 4:10 PM EST-- MoveDMDSM trial of CAT-1004 in Duchenne Muscular Dystrophy (DMD) Progressing --
-- Orphan, Rare Pediatric Disease and Fast Track Designations Received for CAT-1004 in DMD --
-- Phase 2a Trial for CAT-2054 in Hypercholesterolemia Actively Recruiting --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a clinical-stage drug... More
